A study of AMO-1 for the treatment of fragile X syndrome

Trial Profile

A study of AMO-1 for the treatment of fragile X syndrome

Planning
Phase of Trial: Phase II

Latest Information Update: 21 Dec 2016

At a glance

  • Drugs AMO 01 (Primary)
  • Indications Fragile X syndrome
  • Focus Adverse reactions
  • Most Recent Events

    • 21 Dec 2016 According to BELLUS Health media release, the company expects to initiate this trial in the first half of 2017.
    • 07 Jun 2016 According to an AMO Pharma media release, the company plans to initiate this study in 2016.
    • 02 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top